SCHEMBL369237

SCHEMBL369237

COC1=N[C@@H](C(C)C)C(OC)=NC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL206183 1.00
SCHEMBL15341654 0.81
SCHEMBL12241744 0.81
SCHEMBL9604976 0.81
SCHEMBL10200821 0.75
SCHEMBL2808933 0.73
SCHEMBL1770651 0.73
SCHEMBL22984154 0.69
SCHEMBL20055507 0.69
SCHEMBL12444210 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 265 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4219511-A1 INTERMEDIATE, PREPARING METHOD THEREOF, AND METHOD OF PREPARING DRUG Heron Neutron Medical Corp. (TW) 2023-08-02 EP claimed
US-20230234973-A1 INTERMEDIATE, PREPARING METHOD THEREOF, AND METHOD OF PREPARING DRUG HERON NEUTRON MEDICAL CORP. (TW) 2023-07-27 US claimed
US-20260098060-A1 MACROCYCLIC CFTR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2026-04-09 US disclosed
EP-4695260-A1 KRAS MODULATING COMPOUNDS GILEAD SCIENCES, INC. (US) 2026-02-18 EP disclosed
US-20250340574-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMA (US) 2025-11-06 US disclosed
US-20250296915-A1 NOVEL AMINO ACID DERIVATIVES PEPTIDREAM INC (JP) 2025-09-25 US disclosed
EP-4587443-A1 MACROCYCLIC CFTR MODULATORS Idorsia Pharmaceuticals Ltd (CH) 2025-07-23 EP disclosed
WO-2025085554-A1 LYSINE ACETYLTRANSFERASE INHIBITORS Kronos Bio, Inc. (US) 2025-04-24 WO disclosed
EP-4504739-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR Vertex Pharmaceuticals Incorporated (US) 2025-02-12 EP disclosed
US-20240417388-A1 BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 CANCER RESEARCH TECH LTD (GB) 2024-12-19 US disclosed
US-12162888-B2 Carboxamides as ubiquitin-specific protease inhibitors VALO HEALTH, INC. (US) 2024-12-10 US disclosed
WO-2003004498-A1 BETA-AMINO TETRAHYDROIMIDAZO (1, 2-A) PYRAZINES AND TETRAHYDROTRIOAZOLO (4, 3-A) PYRAZINES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES MERCK & CO., INC. (US) 2003-01-16 WO disclosed
EP-0934286-B1 3-ALKOXYISOXAZOL-4-YL-SUBSTITUTED 2-AMINO CARBOXYLIC ACID COMPOUNDS LUNDBECK & CO AS H (DK) 2003-01-08 EP disclosed
US-20010027174-A1 Neo-tryptophan MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH MINNESOTA CORPORATION 2001-10-04 US disclosed
EP-1067950-A4 NEO-TRYPTOPHAN MAYO FOUNDATION FOR MEDICAL (US) 2001-09-05 EP disclosed
US-6214790-B1 POLYPEPTIDES OF NEOTRYPTOPHAN AND SYNTHESIS MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH 2001-04-10 US disclosed
US-6200999-B1 ALZHEIMER*S, HUNTINGTON*S, AND PARKINSON*S DISEASE; ANTIEPILEPTIC, ANALGESIC, ANXIOLYTIC, ANTIISCHEMIC AND ANTIDEPRESSANT AGENTS; NMDA AND AMPA RECEPTOR LIGANDS H. LUNDBECK A/S (DK) 2001-03-13 US disclosed
EP-1067950-A1 NEO-TRYPTOPHAN MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2001-01-17 EP disclosed
CN-1238766-A 3-Alkoxyisoxazol-4-yl-substituted-2-aminocarboxylic acid compounds LUNDBECK & CO AS H (DK) 1999-12-15 CN disclosed
WO-1999052539-A1 NEO-TRYPTOPHAN MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 1999-10-21 WO disclosed